Spatial Genomics Market Analysis: Growth Drivers and Opportunities
The global spatial genomics and transcriptomics market is projected to reach USD 800 million by 2027 from USD 355 million in 2022, at a CAGR of 17.6% during the forecast period. Market growth is largely driven by the increasing development in the area such as neurodegenerative diseases and cancer. Along with this, launch of several advanced products are contributing towards the growth of the market. On the other hand, need of high initial investments, and dearth of skilled professionals are some factors limiting the market growth.
The market for spatial genomics & transcriptomics is highly consolidated, with key players strategizing to capture the market. Prominent players in the market are NanoString Technologies, Inc. (US), 10X Genomics (US), Illumina (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), Standard BioTools Inc. (US), Genomic Vision SA (France), Akoya Biosciences, Inc. (US), Danaher Corporation (US), Natera, Inc. (US), PerkinElmer, Inc. (US), Seven Bridges Genomics (US), S2 Genomics, Inc. (US), Cantata Bio (US), Vizgen Corporation (US), BioSpyder Technologies Inc. (US), Optical Biosystems Inc. (US), Miltenyi Biotec (Germany), Ultivue Inc. (US), Lunaphore Technologies SA (Switzerland), Rebus Biosystems LLC (US), Resolve Biosciences (Germany), Singular Genomics, Inc. (US), and Veracyte (US).
NanoString Technologies, Inc. (US)
NanoString provides life science tools for translational research. The company is engaged in developing, manufacturing, and commercializing instruments, consumables, and services for simultaneously profiling gene and protein activity from a single tissue sample. In 2019, the company launched the GeoMx Digital Spatial Profiler, enabling highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections. The company operates in the spatial genomics and transcriptomics market through its Product segment.
NanoString achieved its 1,000th placement of the nCounter in 2020; the installed base for Chromium reached 1,105 by Q3 of 2022. Similarly, the company achieved robust placements for its GeoMx Digital Spatial profiler (DSP) systems. The installed base for GeoMx jumped to 255 units in 2021 from 130 units in 2020, showcasing its strength in the instruments business. In February 2021, NanoString launched Whole Transcriptome Atlases, which drove a steady increase in the demand for GeoMx consumables since its launch at the Third Annual Spatial Genomics Summit.
10X Genomics (US)
10x Genomics accounted for the second-largest share in the global spatial genomics and transcriptomics market in 2021. 10x Genomics offers the Visium Spatial platform and consumables such as Visium Spatial Gene Expression assays and Visium mRNA arrays to measure spatial gene expression patterns using high-density DNA barcode sequencing arrays. The company acquired Spatial Transcriptomics (Sweden) in 2018 and entered the spatial genomics and transcriptomics market. Its unique position and leadership in single-cell analysis have paved the way for developing spatial technologies. While the company does not offer spatial transcriptomic solutions at the single-cell level, its expertise offers 10x Genomics a competitive edge in the market.
DRIVER: Increasing adoption of spatial genomics & transcriptomics in drug discovery & development
In recent years, spatial genomics and transcriptomics have shifted from strictly research applications to drug discovery & development applications. Genomics and transcriptomics are major tools for accelerating drug discovery & development processes. Spatial techniques are presently in use to enhance the understanding of infectious diseases. Applications of spatial genomics & transcriptomics are expanding with time, targeted towards generating insights into neurodegenerative diseases and cancer. Spatial genomics and transcriptomics is also anticipated to address the one of the current unmet clinical needs in the field of oncology, which is the need for predictive biomarkers of response. These biomarkers assist in developing immunotherapies by offering a greater understanding of the microenvironment of tumor.
Related News
https://www.marketsandmarkets.com/Market-Reports/spatial-genomics-transcriptomics-market-170900551.html
https://www.marketsandmarkets.com/PressReleases/spatial-genomics-transcriptomics.asp
https://www.marketsandmarkets.com/ResearchInsight/spatial-genomics-transcriptomics-market.asp